Zydus Lifesciences Expands US Portfolio with Methenamine Hippurate Tablet Approval

Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Methenamine Hippurate Tablets USP, 1 gram. 

Details of the Drug

This drug, the generic version of Hiprex® Tablets, is used for the prophylactic or suppressive treatment of recurrent urinary tract infections (UTIs) when long-term therapy is required. The tablets will be manufactured at Zydus Lifesciences Ltd (SEZ), Ahmedabad.

Methenamine Hippurate tablets had annual sales of ~USD 32.6 million in the United States as of January 2025, according to IQVIA MAT data. With this latest approval, Zydus Lifesciences now holds a total of 419 USFDA approvals and has filed 483 Abbreviated New Drug Applications (ANDAs) since the filing process began in FY 2003-04. This milestone further strengthens Zydus’ presence in the U.S. generics market.

Zynext Ventures’ Investment in Illexcor Therapeutics

In another filing, the company informed that Zynext Ventures USA LLC, the venture capital arm of Zydus Lifesciences, has announced an investment in Illexcor Therapeutics, a biopharmaceutical company developing next-generation oral therapies for sickle cell disease (SCD). This strategic investment aligns with Zynext Ventures’ commitment to fostering breakthrough innovations in healthcare.

Illexcor is currently developing a first-in-class oral drug targeting the root cause of SCD. Their lead asset, now in preclinical development, is designed to bind to Hemoglobin S and prevent polymerization and sickling, potentially offering disease-modifying benefits.

Sickle cell disease affects up to 10 million people worldwide, significantly reducing quality of life and life expectancy. With the need for more effective treatments, Zydus’ investment in Illexcor highlights its dedication to addressing critical unmet medical needs and advancing innovative therapies.

Conclusion 

With the USFDA approval for Methenamine Hippurate tablets and its investment in Illexcor Therapeutics, Zydus Lifesciences continues to strengthen its global footprint. 

On March 13, 2025, Zydus Lifesciences share price opened at ₹895.00, up from its previous close of ₹888.25. At 9:37 AM, the share price of Zydus Lifesciences was trading at ₹893.70, up by 0.61% on the NSE.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.